PURPOSE: To determine the feasibility and toxicity of delivering stereotactic radiosurgery to patients with locally advanced pancreatic cancer. METHODS AND MATERIALS: Patients with Eastern Cooperative Oncology Group performance status < or=2 and locally advanced pancreatic cancer were enrolled on this Phase I dose escalation study. Patients received a single fraction of radiosurgery consisting of either 15 Gy, 20 Gy, or 25 Gy to the primary tumor. Acute gastrointestinal toxicity was scored according to the Radiation Therapy Oncology Group criteria. Response to treatment was determined by serial high-resolution computed tomography scanning. RESULTS: Fifteen patients were treated at 3 dose levels (3 patients received 15 Gy, 5 patients received 20 Gy, and 7 patients received 25 Gy). At these doses, no Grade 3 or higher acute gastrointestinal toxicity was observed. This trial was stopped before any dose-limiting toxicity was reached, because the clinical objective of local control was achieved in all 6 evaluable patients treated at 25 Gy. CONCLUSIONS: It is feasible to deliver stereotactic radiosurgery to patients with locally advanced pancreatic cancer. The recommended dose to achieve local control without significant acute gastrointestinal toxicity is 25 Gy.
PURPOSE: To determine the feasibility and toxicity of delivering stereotactic radiosurgery to patients with locally advanced pancreatic cancer. METHODS AND MATERIALS: Patients with Eastern Cooperative Oncology Group performance status < or=2 and locally advanced pancreatic cancer were enrolled on this Phase I dose escalation study. Patients received a single fraction of radiosurgery consisting of either 15 Gy, 20 Gy, or 25 Gy to the primary tumor. Acute gastrointestinal toxicity was scored according to the Radiation Therapy Oncology Group criteria. Response to treatment was determined by serial high-resolution computed tomography scanning. RESULTS: Fifteen patients were treated at 3 dose levels (3 patients received 15 Gy, 5 patients received 20 Gy, and 7 patients received 25 Gy). At these doses, no Grade 3 or higher acute gastrointestinal toxicity was observed. This trial was stopped before any dose-limiting toxicity was reached, because the clinical objective of local control was achieved in all 6 evaluable patients treated at 25 Gy. CONCLUSIONS: It is feasible to deliver stereotactic radiosurgery to patients with locally advanced pancreatic cancer. The recommended dose to achieve local control without significant acute gastrointestinal toxicity is 25 Gy.
Authors: Kush Goyal; Douglas Einstein; Rafael A Ibarra; Min Yao; Charles Kunos; Rod Ellis; James Brindle; Deepjot Singh; Jeffrey Hardacre; Yuxia Zhang; Jeffrey Fabians; Gary Funkhouser; Mitchell Machtay; Juan R Sanabria Journal: J Surg Res Date: 2011-09-05 Impact factor: 2.192
Authors: Vivek Verma; Audrey J Lazenby; Dandan Zheng; Abhijeet R Bhirud; Quan P Ly; Chandrakanth Are; Aaron R Sasson; Chi Lin Journal: Radiother Oncol Date: 2017-01-12 Impact factor: 6.280
Authors: Anusha Kalbasi; Chad Komar; Graham M Tooker; Mingen Liu; Jae W Lee; Whitney L Gladney; Edgar Ben-Josef; Gregory L Beatty Journal: Clin Cancer Res Date: 2016-06-28 Impact factor: 12.531
Authors: Shalini Moningi; Avani S Dholakia; Siva P Raman; Amanda Blackford; John L Cameron; Dung T Le; Ana M C De Jesus-Acosta; Amy Hacker-Prietz; Lauren M Rosati; Ryan K Assadi; Shirl Dipasquale; Timothy M Pawlik; Lei Zheng; Matthew J Weiss; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman Journal: Ann Surg Oncol Date: 2015-01-07 Impact factor: 5.344
Authors: Ziwei Feng; Avani D Rao; Zhi Cheng; Eun Ji Shin; Joseph Moore; Lin Su; Seong-Hun Kim; John Wong; Amol Narang; Joseph M Herman; Todd McNutt; Dengwang Li; Kai Ding Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-19 Impact factor: 7.038
Authors: William A Hall; Lauren E Colbert; Dana Nickleach; Jeffrey Switchenko; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; Claire Hardy; David A Kooby; Roshan S Prabhu; John Kauh; Jerome C Landry Journal: J Gastrointest Oncol Date: 2014-04
Authors: Aaron T Wild; Susan M Hiniker; Daniel T Chang; Phuoc T Tran; Mouen A Khashab; Maneesha R Limaye; Daniel A Laheru; Dung T Le; Rachit Kumar; Jonathan S Pai; Blaire Hargens; Andrew B Sharabi; Eun Ji Shin; Lei Zheng; Timothy M Pawlik; Christopher L Wolfgang; Albert C Koong; Joseph M Herman Journal: J Gastrointest Oncol Date: 2013-12